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Bile acids, bile alcohols, and hormonal steroids represent the ultimate biologically active products of
cholesterol metabolism in vertebrates. However, intermediates in their formation, including oxysterols
and cholestenoic acids, also possess known, e.g., as ligands to nuclear and G-protein-coupled receptors,
and unknown regulatory activities. The potential diversity of molecules originating from the cholesterol
structure is very broad and their abundance in biological materials ranges over several orders of
magnitude. Here we describe the application of enzyme-assisted derivatization for sterol analysis
(EADSA) in combination with liquid chromatography–electrospray ionization–mass spectrometry to
deﬁne the oxysterol and cholestenoic acid metabolomes of human plasma. Quantitative proﬁling of
adult plasma using EADSA leads to the detection of over 30 metabolites derived from cholesterol,
some of which are ligands to the nuclear receptors LXR, FXR, and pregnane X receptor or the
G-protein-coupled receptor Epstein–Barr virus-induced gene 2. The potential of the EADSA technique
in screening for inborn errors of cholesterol metabolism and biosynthesis is demonstrated by the
unique plasma proﬁle of patients suffering from cerebrotendinous xanthomatosis. The analytical
methods described are easily adapted to the analysis of other biological ﬂuids, including cerebrospinal
ﬂuid, and also tissues, e.g., brain, in which nuclear and G-protein-coupled receptors may have important
regulatory roles.
& 2012 Elsevier Inc. All rights reserved.Introduction
Oxysterols and their downstream metabolites, including choles-
tenoic acids, represent important biologically active components of
plasma. These molecules are of increasing interest to bioscientists on
account of their important signaling roles in the immune system
[1–3], as agonists to nuclear receptors [4–7], and as markers ofll rights reserved.
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Grifﬁths).oxidative stress [8], atherosclerosis [9,10], and neurodegenerative
disease [11]. Oxysterols can be formed from cholesterol and
its sterol precursors both enzymatically and nonenzymatically.
In vertebrates, the ﬁrst step of all cholesterol metabolism leads to
the formation of an oxysterol. 22R-Hydroxycholesterol and 20R,22R-
dihydroxycholesterol are the precursors of pregnenolone and steroid
hormones [12], whereas 7a-, 24S-, 25-, and (25R),26-hydroxycholes-
terols all represent precursors of bile acids [13]. Some of these
oxysterols and their downstream metabolites are ligands to nuclear
receptors, e.g., liver X receptors (LXRs)1 [5,6], farnesoid X receptor
(FXR) [7], pregnane X receptor [4,14], vitamin D receptor [15], and
other receptors involved in lipid homeostasis, e.g., INSIG [16,17], and
also G-protein-coupled receptors [2,18,19]. Oxysterols also play a role
in the immune response [1,20,21], in which, e.g., 25-hydroxycholes-
terol is secreted by macrophages in response to Toll-like receptor
activation and suppresses immunoglobulin A production, whereas its
metabolite 7a,25-dihydroxycholesterol directs B-cell migration [1,3].
Clearly, the presence of these regulatory molecules in biological ﬂuids
is of major physiological importance and analytical methods are
required to reliably identify and quantify such molecules.
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chromatography (GC)–mass spectrometry (MS), after saponiﬁcation
and derivatization, utilizing selected ion recording (SIR) to attain
the necessary sensitivity [22], although liquid chromatography
(LC)–MS methods utilizing SIR or multiple reaction monitoring
(MRM) are gaining popularity [23–25]. To improve MS response
in LC–electrospray ionization (ESI)–MS studies a number of groups
are now exploiting derivatization methods to enhance ionization
[26–29]. Cholestenoic acids are usually analyzed by GC–MS in an
analysis separate from oxysterols [30], this is on account of different
requirements of sample preparation. However, Axelson and collea-
gues developed a GC–MS assay for C27 acids in blood and plasma [31],
which was extended to include some oxysterols.
Oxysterols represent just one subgroup of the lipidome, and
in recent years lipidomics has become a ﬁeld of great activity in,
and intense interest to, the bioscience community [32–35].
Many of the lipidomic studies performed have been on bioﬂuids,
particularly plasma or serum [25]. The dominant technology has
been ESI-MS. ESI-MS analysis has been performed linked to LC,
i.e., LC-ESI-MS, and also in a stand-alone direct infusion mode.
Stand-alone, or shotgun, lipidomics offers the advantage of
simplicity, but is unable to differentiate between isobaric
metabolites. Interfacing ESI with LC separation can overcome
this shortcoming, but introduces some added complexity to
the analysis. GC–MS offers an alternative analytical method;
however, the requirements of solvolysis and/or hydrolysis
followed by derivatization, often of multiple functional groups
with freshly prepared reagents and solvents, discourage many
would-be analysts [36].
Any lipidomic experiment consists of essentially three key
stages: (i) lipid extraction, (ii) lipid analysis, and (iii) lipid
quantiﬁcation. Clearly the extremely different physical properties
of many lipids and their presence in cells, tissues, and body ﬂuids
at widely different levels make analysis of the global lipidome
extremely challenging. An alternative to global lipidomics is to
adopt a targeted approach. Here a particular class of lipid is
targeted, usually based on physicochemical properties. This is the
approach adopted by many lipid scientists [32,33,37]. Whereas
glycerolipids, glycerophospholipids, and sphingolipids are often
well represented in global ESI-MS-based lipidomic studies, this is
not true of members of the other classes [38]. The explanation for
this is simple; most ESI-MS methods are biased toward the most
abundant and readily ionized compounds. Cholesterol and some
of its metabolites are present at high levels in blood and plasma
but are barely detectable in a global lipidomics experiment based
on the ESI-MS analysis of these ﬂuids. This is on account of
difﬁculties experienced in sample handling and poor ionization
characteristics of sterols. Whereas established MS methods exist
for analysis of the ultimate products of cholesterol metabolism,
i.e., hormonal steroids and bile acids [39], methods for the
analysis of intermediates in their biosynthesis, i.e., oxysterols
and cholestenoic acids, are less mature, and to date this region of
the lipidome has been largely ignored.
Over the past decade we have developed targeted methods for
sterol, oxysterol, and cholestenoic acid analysis, which we have
exploited in the analysis of brain tissue, cerebrospinal ﬂuid, plasma/
serum, cells, and cell media [40–45]. Our methodology is based on
separating oxysterols and cholestenoic acids from cholesterol in the
ﬁrst step of the sample preparation process. This avoids the
potential problem of cholesterol autoxidation generating oxysterols
nonenzymatically with structures similar to those formed endogen-
ously [46] and allows the subsequent storage of oxysterols without
the possibility of their formation via cholesterol and air. Oxysterols
are then activated to allow subsequent ‘‘click chemistry’’ with a
charge-baring group, which enhances their ESI-MS response. In our
experience, unprocessed samples can be stored effectively at 80 1Cbefore sample preparation with minimal autoxidation. However,
growing peaks corresponding to 7-oxocholesterol, 7b-hydroxycho-
lesterol, 5,6-epoxycholesterol, and cholestane-3b,5a,6b-triol should
alert the analyst of potential autoxidation problems.Note on nomenclature
Here we regard a steroid as a molecule based on the cyclo-
pentanoperhydrophenanthrene ring structure. In vertebrates
hormonal steroids usually contain 18, 19, or 21 carbon atoms;
bile acids 24 carbon atoms with a carboxylic acid group at C-24;
and cholestanoic and cholestenoic acids 27 carbon atoms with an
acid group at C-26 or C-27. In cholestenoic acids the stereo center
at C-25 is usually 25R. Endogenous sterols are precursors or
metabolites of cholesterol and include cholestenoic acids, which,
like cholesterol, possess a hydroxy (or oxo) group at C-3 and
usually contain 27 carbons. Oxysterols are a category of sterols,
mostly derived from cholesterol, containing an additional oxygen
function. In this article we have adopted the nomenclature
recommended by the Lipid Maps Consortium [37].Principles
In this article we describe a LC-ESI-MS method for the quanti-
tative proﬁling of a wide range of oxysterols and their downstream
acidic metabolites from microliter quantities of plasma. Our method
is based on ethanol extraction, separation of cholesterol metabolites
from cholesterol itself by reversed-phase (RP) solid-phase extraction
(SPE), followed by enzyme-assisted derivatization for sterol analysis
(EADSA). EADSA consists of enzymatic conversion of 3b-hydroxy-5-
ene- and 3b-hydroxy-5a-hydrogen-containing sterols to 3-oxo-4-
ene and 3-oxo sterols followed by tagging a positively charged
quaternary nitrogen group to the resulting oxo group in a ‘‘click
reaction’’ (Scheme 1). Analysis and quantiﬁcation are performed by
LC-ESI-MS. Our preference is to perform mass analysis at high mass
resolution (30,000, full width at half-maximum height, FWHM)
using stable-isotope or structural analogue internal standards for
quantiﬁcation, with compound identiﬁcation achieved using exact
mass measurements (o5 ppm) and multistage fragmentation
(MSn). We perform these analyses on an LTQ-Orbitrap instrument.
Alternative MS formats can be used, such as quadrupole–time-of-
ﬂight (Q-TOF), tandem quadrupole, and cylindrical or linear ion trap
(LIT), but none of these offers the combination of high-resolution
exact mass measurements and MSn provided by LTQ-Orbitrap or
LTQ-FT-ICR instruments. We complement the EADSA LC-ESI-MS
method with shotgun ESI-MS, also performed at high resolution
with exact mass measurement and MS2, to characterize oxysterols
and their downstream metabolites conjugated with sulfuric and/or
glucuronic acids. Shotgun ESI-MS is appropriate for analysis of
cholesterol metabolites sulfated at C-3 and thus inaccessible to
EADSA. Using shotgun ESI-MS we do not attempt to exactly identify
or quantify conjugated oxysterols on account of an absence of
authentic standards. Ongoing work is in progress to rectify this
situation by the synthesis of appropriate standards.Materials
High-performance liquid chromatography (HPLC)-grade water,
absolute ethanol, and other HPLC-grade solvents were from Fisher
Scientiﬁc (Loughborough, UK) or Sigma–Aldrich (Dorset, UK). Acetic
acid was AnalaR NORMAPUR grade (BDH, VWR, Lutterworth, UK).
Authentic sterols, steroids, bile acids, and their precursors were from
Avanti Polar Lipids (Alabama, USA), Steraloids, Inc. (Rhode Island,
USA), Sigma–Aldrich, or previous studies in our laboratories [41].
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Scheme 1. Enzyme-assisted derivatization for sterol analysis. Sterols possessing a 3b-hydroxy-5-ene function are oxidized with cholesterol oxidase (from Streptomyces sp.),
and the resulting 3-oxo-4-ene group is then derivatized with Girard P (GP) hydrazine in a ‘‘click reaction’’ [42]. The cholesterol oxidase enzyme is also active toward sterols
with a 3b-hydroxy-5a-hydrogen function generating 3-oxo sterols [47]. Sterols naturally containing an oxo group can be derivatized with GP hydrazine in the absence of
cholesterol oxidase. Once derivatized, sterols are analyzed by LC-ESI-MS and MSn. The derivatization procedure is exempliﬁed by 3b-hydroxycholest-(25R)-5-en-26-oic acid.
The nomenclature recommended by Lipid Maps has been adopted, by which a hydroxyl group attached to the terminal carbon of the cholestene side chain introducing
the R conﬁguration at C-25 is said to be attached to C-26. This nomenclature is also extended to C27 acids [37].
Table 1
Suppliers of reagents and materials.
Material Supplier Cat. No
24(R/S)-[26,26,26,27,27,27-2H6]Hydroxycholesterol
a Avanti Polar Lipids 700049P
24(R/S)-[25,26,26,26,27,27,27-2H7]Hydroxycholesterol
a Avanti Polar Lipids 700018P
http://avantilipids.com/index.php?option=com_content&view=article&id=2323&Itemid=305&catnumber=700018
[25,26,26,26,27,27,27-2H7]Cholesterol Avanti Polar Lipids 700041P
http://avantilipids.com/index.php?option=com_content&view=article&id=693&Itemid=305&catnumber=700041
Girard P reagent TCI Europe G0030
http://www.tcieurope.eu/en/catalog/G0030.html
Cholesterol oxidase from Streptomyces sp. Sigma–Aldrich C8868
http://www.sigmaaldrich.com/catalog/product/sigma/c8649?lang=en&region=GB
Certiﬁed Sep-Pak C18 200-mg, 3-ml, VAC cartridges Waters 186004618
http://www.waters.com/waters/partDetail.htm?partNumber=186004618
BD Biosciences Luer-lock syringe Sigma–Aldrich Z192120-100EA
http://www.sigmaaldrich.com/catalog/product/aldrich/z192120?lang=en&region=GB
Corning 15-ml centrifuge tube Fisher Scientiﬁc CFT-420-031Y
https://extranet.ﬁsher.co.uk/insight2_uk/mainSearch.do
Corning 50-ml centrifuge tube Fisher Scientiﬁc CFT-900-031F
https://extranet.ﬁsher.co.uk/insight2_uk/mainSearch.do
Greiner 12-ml round-bottom tubes, polypropylene Sigma–Aldrich Z642975
http://www.sigmaaldrich.com/catalog/product/sigma/z642975?lang=en&region=GB
Cultubes 4-ml polypropylene tube Simport Plastics T415-2A
http://www.bioventures.com/_pdf/Simport-Scientiﬁc-Catalog.pdf
Microcentrifuge tubes Fisher Scientiﬁc TUL-150-290U
https://extranet.ﬁsher.co.uk/insight2_uk/getProduct.do?productCode=TUL-150-290U&resultSetPosition=26
a 24(R/S)-[26,26,26,27,27,27-2H6]Hydroxycholesterol is no longer commercially available and has been replaced by 24(R/S)-[25,26,26,26,27,27,27-
2H7]hydroxycho-
lesterol.
W.J. Grifﬁths et al. / Free Radical Biology and Medicine 59 (2013) 69–84 71Girard P (GP) reagent (1-(carboxymethyl)pyridinium chloride hydra-
zide) was from TCI Europe (Oxford, UK) and cholesterol oxidase
from Streptomyces sp. was from Sigma–Aldrich. Certiﬁed Sep-Pak C18
200-mg cartridges were from Waters (Elstree, UK). Luer-locksyringes were from BD Biosciences (Sigma–Aldrich). All plastic
materials used were made of polypropylene. Latex-containing
material, including gloves, should be avoided. Further supplier
details including Web addresses are given in Table 1.
Plasma
C18SPE-1
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Cholesterol oxidase (in
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Scheme 2. Sample preparation method for analysis of sterols in plasma.
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Sample preparation
The following instruments were used in the sample prepara-
tion steps: ultrasonic bath, Grant XB3 (VWR Jencons); multispeed
refrigerated centrifuge, ALC, PK12R; vacuum manifold (Agilent
Technologies); ScanLaf ScanSpeed vacuum concentrator; vortex
mixer.
Sample analysis
Chromatographic separation of derivatized sterols was per-
formed on either an UltiMate 3000 HPLC system or an UltiMate
3000 Binary RSLCnano system, both operated with a conventional
ﬂow rate conﬁguration (both from Dionex, Surrey, UK) utilizing a
Hypersil GOLD RP column (1.9-mm particles, 502.1 mm; Fisher
Scientiﬁc, Loughborough, UK). MS analysis was performed with
the chromatographic eluent directed to the atmospheric pressure
ionization (API) source of an LTQ-Orbitrap XL or LTQ-Orbitrap
Velos MS (Thermo Fisher, San Jose, CA, USA). These instruments
have the hybrid linear ion-trap–Orbitrap analyzer format. The
Orbitrap is a Fourier transform (FT) mass analyzer capable of high
resolution (up to 100,000 FWHM) and exact mass measurement
(o5 ppm).
Although the work described in this article employed LTQ-
Orbitrap instruments the methodology can also be exploited using
tandem-quadrupole, Q-TOF, and ion trap instruments [41,44].Protocol
Extraction of plasma for analysis of sterols
Plasma (100 ml) was added drop-wise into a 2-ml microcentrifuge
tube (Eppendorf, Cambridge, UK) containing 1.05ml of absolute
ethanol containing 5 ml of 24(R/S)-[26,26,26,27,27,27-2H6]hydroxy-
cholesterol (Avanti Polar Lipids) in propan-2-ol (4 ng/ml) in an
ultrasonic bath and sonicated for 5 min (empirically we have found
that drop-wise addition of plasma to ethanol is important to max-
imize the extraction of sterols from plasma proteins). The resultant
solution was diluted to 70% (v/v) ethanol by the addition of 0.35ml of
water, ultrasonicated for a further 5min, and centrifuged at 14,000g
at 4 1C for 30 min. If cholesterol or sterols of similar polarity are the
object of the study then 5 ml of [25,26,26,26,27,27,27-2H7]cholesterol
(Avanti Polar Lipids) in propan-2-ol (4 mg/ml) is added with 24(R/S)-
[26,26,26,27,27,27-2H6]hydroxycholesterol to the ethanol solvent.
A 200-mg Certiﬁed Sep-Pak C18 cartridge (Waters) was rinsed
with 4 ml of absolute ethanol followed by 6 ml of 70% ethanol (v/
v). Plasma in 70% ethanol (1.5 ml) was applied to the cartridge
and allowed to ﬂow at a rate of 0.25 ml/min (although this ﬂow
rate is rather slow, it provides secure extraction of the desired
analytes on the SPE column). Flow was aided by application of a
slight pressure from a BD Biosciences Luer-lock syringe (Sigma–
Aldrich). Alternatively, ﬂow was assisted by the use of a vacuum
manifold providing a negative pressure at the column outlet. The
ﬂowthrough (1.5 ml) and a column wash of 5.5 ml of 70% ethanol
were collected in a 15-ml Corning centrifuge tube (Fisher Scien-
tiﬁc) or 12-ml Greiner tube (Sigma–Aldrich) (i.e., SPE-1-Fr-1, 7 ml
70% ethanol; Scheme 2). By testing the method with a solution of
cholesterol and 24(R/S)-[26,26,26,27,27,27-2H6]hydroxycholes-
terol in 70% ethanol, we found that cholesterol was retained
on the column even after the 5.5-ml column wash, whereas
24(R/S)-[26,26,26,27,27,27-2H6]hydroxycholesterol elutes in the
ﬂowthrough and column wash. After a further column wash with
4 ml of 70% ethanol (SPE-1-Fr-2), cholesterol was eluted from thecolumn in 2 ml of absolute ethanol (SPE-1-Fr-3). The column was
further stripped with an additional 2 ml of absolute ethanol to
elute more hydrophobic sterols (SPE-1-Fr-4). Each fraction was
divided into two subfractions, A and B, and transferred by pipette
(using polypropylene tips) into 4-ml polypropylene Cultubes
(Simport, Beloeil, QC, Canada) or 12-ml Greiner tubes and dried
under reduced pressure using a vacuum concentrator (Scheme 2).
The entire procedure was repeated with an additional 50 or
100 ml of plasma, but the ﬁnal division into A and B subfractions
followed by drying down was omitted to leave an intact
fraction C.
Enzyme-assisted derivatization
The dried sterol fractions A from above were reconstituted in
100 ml of propan-2-ol and vortex mixed thoroughly (2 min), and
1 ml of 50 mM phosphate buffer (KH2PO4, pH 7; Sigma–Aldrich)
containing 3.0 ml of cholesterol oxidase from Streptomyces
sp. (2 mg/ml in H2O, 44 U/mg protein) was added to each. After
a further vortex (2 min), the mixture was incubated at 37 1C for
1 h and then quenched with 2 ml of methanol. Glacial acetic acid
(150 ml) was added to the reaction mixture above (now in 70%
methanol, v/v) followed by 150 mg of GP reagent. The mixture
was thoroughly vortexed (2 min) and incubated at room tem-
perature overnight in the dark. For the treatment of fractions B
cholesterol oxidase was omitted from the procedure.
SPE of derivatized sterols
Even when derivatized with GP reagent, sterols may be
difﬁcult to solubilize (or retain in solution) when using a highly
aqueous mixture of methanol and water. This can make the
extraction of the desired analytes using RP-SPE challenging, as
insoluble material will not be extracted by the stationary phase of
the column and will be lost from the analysis. To circumvent this
problem a recycling procedure was used [41,45].
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with 6 ml of 100% methanol, 6 ml of 10% methanol (v/v), and
conditioned with 4 ml of 70% methanol (v/v). The derivatization
mixture from above (3 ml of 70% methanol, 5% acetic acid, 3%
propanol-2-ol, containing 150 mg of GP reagent and 6 mg of
cholesterol oxidase) was applied to the column followed by
1 ml of 70% methanol (used to rinse the reaction tube) and 1 ml
of 35% methanol. The combined efﬂuent (5 ml) was collected in a
15-ml Corning polypropylene tube and diluted with water (4 ml)
to give 9 ml of 35% methanol. The resulting solution was again
applied to the column followed by a wash with 1 ml of 17%
methanol. The combined efﬂuent (10 ml) was added to 9 ml of
water in a 50-ml Corning polypropylene tube (or divided into two
5-ml aliquots and decanted into two 12-ml Greiner polypropy-
lene tubes each containing 4.5 ml of water) to give 19 ml of
17.5% methanol. This solution was again applied to the column
followed by a wash with 6 ml of 10% methanol. At this point all
the derivatized sterols were extracted by the column and excess
derivatization reagent was in the ﬂowthrough and wash. Deriva-
tized sterols were then eluted in three 1-ml portions of 100%
methanol and collected in microcentrifuge tubes (SPE-2-Fr-1, -Fr-
2, -Fr-3) and combined (either as SPE-2-Fr-1,2 or as SPE-2-Fr-
1,2,3); any remaining sterols were eluted with 1 ml of absolute
ethanol (SPE-2-Fr-4). LC-MSn analysis revealed that the deriva-
tized oxysterols were present in the ﬁrst 2 ml of methanol eluent
(SPE-2-Fr-1, SPE-2-Fr-2), whereas derivatized cholesterol also
tailed into the third milliliter (SPE-2-Fr-3). Acidic sterols eluted
predominantly in the ﬁrst milliliter of methanol (SPE-2-Fr-1).
To differentiate sterols that naturally possess a 3-oxo function
from those oxidized to contain one, samples were analyzed in
parallel in the presence (fractions A, e.g., SPE-1-Fr-1A) and
absence (fractions B, e.g., SPE-1-Fr-1B) of cholesterol oxidase
(see Scheme 2).
SPE of Underivatized sterols
Sterols in fraction C were extracted and recycled on a second
SPE column essentially as described for the derivatized sterols.
An initial solution of 70% ethanol was applied to the column,
eluted, and diluted to 23% ethanol/11% methanol/66% H2O (v/v/v).
This procedure was repeated to give an 11% ethanol/6% methanol/
83% H2O solution at which point all sterols were extracted by the
column. After a wash with 10% methanol the sterols were eluted
with four 1-ml portions of methanol and combined.
LC-ESI-MSn on the LTQ-Orbitrap
Chromatographic separation of GP-tagged sterols was per-
formed on either an UltiMate 3000 HPLC system or an UltiMate
3000 Binary RSLCnano system (both Dionex) utilizing a Hypersil
GOLD RP column (1.9-mm particles, 502.1 mm; Fisher Scienti-
ﬁc). Mobile phase A consisted of 33.3% methanol, 16.7% acetoni-
trile, containing 0.1% formic acid, and mobile phase B consisted of
63.3% methanol, 31.7% acetonitrile containing 0.1% formic acid.
After 1 min at 20% B, the proportion of B was raised to 80% B over
the next 7 min and maintained at 80% B for a further 5 min, before
returning to 20% B in 6 s and reequilibrating for a further 3 min 54
s, giving a total run time of 17 min. The ﬂow rate was maintained
at 200 ml/min and the eluent directed to the API source of an LTQ-
Orbitrap XL or LTQ-Orbitrap Velos (both Thermo Fisher, San Jose,
CA, USA) MS.
The Orbitrap was calibrated externally before each analytical
session. Mass accuracy was in general better than 5 ppm on the
XL and better than 1 ppm on the Velos during the entire analytical
session. For LC-ESI-MS and LC-ESI-MSn analysis of reference
compounds, sample (1 pg/ml in 60% methanol, 0.1% formic acid)was injected (20 ml) onto the RP column and eluted into the
LTQ-Orbitrap at a ﬂow rate of 200 ml/min. For the analysis of
GP-tagged oxysterols and cholestenoic acids from plasma, 12 ml of
the combined methanol fractions (2 ml) from the second Sep-Pak
C18 cartridge (SPE-2-Fr-1,2; equivalent to 0.3 ml of plasma assum-
ing all the relevant sterols elute in the ﬁrst two methanol
fractions) was diluted with 8 ml 0.1% formic acid and 20 ml
injected onto the LC column. Two experimental methods were
utilized. In the ﬁrst experimental method (Experiment 1) three
scan events were performed: ﬁrst an FT-MS scan in the Orbitrap
analyzer over the m/z range 400–650 (or 300–800) at 30,000
resolution (FWHM) with a maximum ion ﬁll time of 500 ms,
followed by data-dependent MS2 and MS3 events performed in
the LIT with maximum ion ﬁll times of 200 ms on the XL and
100 ms on the Velos. For the MS2 and MS3 scans performed on the
XL, three microscans were performed, whereas only one micro-
scan was required by the Velos; the precursor-ion isolation width
was set at 2 (to select the monoisotopic ion) and the normalized
collision energy was at 30 and 35 (instrument settings), respec-
tively. A precursor-ion include list was deﬁned according to the
m/z of the [M]þ ions of predicted sterols so that MS2 was
preferentially performed on these ions in the LIT if their intensity
exceeded a preset minimum (500 counts). If a fragment ion
corresponding to a neutral loss of 79 Da from the precursor ion
was observed in the MS2 event and was above a minimal signal
setting (200 counts), MS3 was performed on this fragment
(Scheme 3). To maximize efﬁciency, the MS2 and MS3 events
were performed in the LIT at the same time that the high-
resolution mass spectrum was being recorded in the Orbitrap.
The second experimental method (Experiment 2) involved a
targeted MRM-like approach. In event 1 the Orbitrap analyzer
was scanned as above, in the second event the MS3 transition, e.g.,
534.4-455.4-, was monitored using collision energies of 30 and
35 for MS2 and MS3, respectively. In the third event another MS3
transition, e.g., 540.4-461.4-, was monitored in a similar
manner (e.g., to accommodate the 24(R/S)-[2H6]hydroxycholes-
terol internal standard). The precursor-ion include list and MRM
transitions utilized for the analysis of plasma are given in
Supplementary Table S1. Other fractions from the SPE columns
were analyzed in an identical fashion.
Shotgun ESI-MS on the LTQ-Orbitrap
Underivatized sterols were analyzed by negative-ion ESI-MS
on the LTQ-Orbitrap XL. Sample introduction was achieved using
an Advion TriVersa NanoMate (Advion BioSciences, USA) ESI chip
utilizing nano-ESI nozzles. Accurate mass spectra (o5 ppm) were
recorded at up to 100,000 (FWHM) resolution over the m/z range
100–1000. Peaks appearing at an m/z appropriate to a C24 or C27
bile acid or sulfated and/or glucuronidated sterol were subjected
to MS2 when of appropriate intensity. MS2 spectra were gener-
ated in the LIT and recorded using either the LIT or the Orbitrap
detector. To avoid the low-mass cutoff inherent to ion traps, MS2
spectra were also recorded in the ‘‘pulsed Q collision induced
dissociation’’ (PQD) mode [48]. In some instances the eluent from
the second Sep-Pak C18 column was concentrated to 100 ml before
analysis to enhance signal intensity.Results
General considerations related to the EADSA methodology
In this article we describe enzyme-assisted derivatization
with charge-tagging using the GP hydrazine reagent (Scheme 1).
The advantages provided by this form of derivatization include:
Scheme 3. Fragmentation of GP-tagged sterols. (A) MS2 ([M]þ-) fragmentation and (B) MS3 ([M]þ-[M79]þ-) fragmentation illustrated for GP-tagged
3b-hydroxycholest-(25R)-5-en-26-oic acid. (C) The effect of 7-hydroxylation is illustrated for GP-tagged 3b,7a-dihydroxycholest-(25R)-5-en-26-oic acid.
W.J. Grifﬁths et al. / Free Radical Biology and Medicine 59 (2013) 69–8474(i) enhanced lipid solubility in solvents used for RP chromato-
graphy; (ii) improved gas-phase ion formation via the ESI process;
(iii) derivative-speciﬁc MS2 spectra, i.e., prominent loss of 79 Da
from the molecular ion; and (iv) structurally informative MS3
([Mþ]-[M-79]þ-) spectra (Scheme 3). A library of MS2 and MS3
spectra of authentic standards can be found at http://sterolana
lysis.org.uk/. The utilization of the MS3 scan provides an extra
dimension of separation as only ions fragmenting in the MS2
event by loss of 79 Da are fragmented further in MS3. A drawback
of the charge-tagging methodology is that sterols with a labile
7-hydroxy group, e.g., 7-hydroxy-3-oxocholest-4-en-26-oic acids,
can dehydrate to a minor extent during sample preparation to
give conjugated dienes. This probably accounts for a proportion of
3-oxocholesta-4,6-dien-26-oic acid found in plasma (Table S2).
A further complication is that 24-oxo-26(or 27) acids eliminate
CO2 to give 26-nor-sterols accounting for the presumptive identi-
ﬁcation of 7a-hydroxy-26-nor-cholest-4-ene-3,24-dione. Similar
decarboxylation reactions of 24-oxo-26 acids have been reported
by Yuri et al. [49], Bun-ya et al. [50], and Karlaganis et al. [51]. The
sample preparation method utilized here has been designed with
oxysterols and their acidic metabolites in mind; however, it is
also applicable to other steroids possessing an oxo group, e.g.,
dehydroepiandrosterone (DHEA), testosterone, or their sulfates.Identiﬁcation and quantiﬁcation
Here we regard a sterol to be ‘‘identiﬁed’’ when its retention
time, exact mass, and MSn spectra are identical to those of the
authentic standard. The term ‘‘presumptively identiﬁed’’ is used
when the retention time, exact mass, and MSn spectra are
compatible with those of the proposed structure, but there is an
absence of authentic standard. Quantiﬁcation of monohydroxy-
cholesterols was achieved by stable-isotope dilution MS using
24(R/S)-[2H6]hydroxycholesterol as the internal standard [45].
Quantitative estimates were made for other cholesterol metabo-
lites; this is possible using 24(R/S)-[2H6]hydroxycholesterol as the
internal standard, as previous studies have shown that GP-tagged
3-oxo-4-ene sterols give a similar mass spectrometric response
irrespective of the other functional groups attached to the steroid
skeleton [43]. For accurate quantiﬁcation calibration curves
should be generated using authentic standards. In this study the
levels of free sterols are measured. Sterols may also be esteriﬁed,
glucuronidated, and/or sulfated. The last two conjugates are
investigated here using shotgun ESI-MS but are not quantiﬁed.
If sterols esteriﬁed to fatty acids are the subject of the study the
intact molecules may be analyzed directly by LC-ESI-MS after
appropriate extraction and puriﬁcation [25]. Alternatively, the
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[52].
Whereas fractions SPE-2-Fr1,2A in the sample preparation
protocol will contain the GP charge-tagged stable-isotope-labeled
standard 24(R/S)-[2H6]hydroxycholesterol, the absence of choles-
terol oxidase in the parallel procedure generating SPE-2-Fr-1,2B
means that 24(R/S)-[2H6]hydroxycholesterol in this fraction is not
derivatized and thus does not act as an internal standard for
quantiﬁcation. One solution to this problem is to generate, e.g., a
22R-[2H7]hydroxycholest-4-en-3-one reference standard from
22R-[2H7]hydroxycholesterol (Avanti Polar Lipids). The isotope-
labeled 3-oxo-4-ene compound can then be added to ethanol
during the initial extraction step and can be used for quantiﬁca-
tion of sterols in SPE-2-Fr-1,2B. Alternatively, DHEA 3-sulfate,
which is abundant in plasma and possesses a 17-oxo group and is
not oxidized further by cholesterol oxidase, will appear in both
SPE-2-Fr-1,2A and SPE-2-Fr-1,2B fractions and can be used to
normalize fraction B to fraction A.
Oxysterols
(25R),26-Hydroxycholesterol is the most abundant oxysterol
present in adult plasma (Fig. 1). The level of free (25R),26-
hydroxycholesterol determined here (19.1270.70 ng/ml, mean
of 84 adult subjects7standard error) is in good agreement with
values of the free oxysterol determined by GC–MS (13–41 ng/ml),
which tend to be about 10% of the combined free and fatty
acid ester values [22,53]. In addition to (25R),26-hydroxycholes-
terol, 7a- (0.8270.39 ng/ml), 24S- (6.8670.31 ng/ml), and80
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Fig. 1. Levels (ng/ml7SE) of free oxysterols and cholenoic and cholestenoic acids measu
3-oxo-4-ene structure and red bars to molecules with a 3b-hydroxy-5-ene function. Sy
S2. Measured values are given in Supplementary Table S2, as are activities as nuclear25-hydroxycholesterols (4.0670.22 ng/ml) were found in adult
plasma (Fig. 2, Table S2). The levels of free 7a-hydroxycholesterol
determined here are somewhat lower than values determined by
GC–MS (7–15 ng/ml), which correspond to about 10–20% of
the combined free and fatty acid ester values [22,25,27,53].
The downstream metabolite 7a-hydroxycholest-4-en-3-one
(2.2970.25 ng/ml) is also found in plasma [53,54].
It should be noted that the methodology described here is
primarily targeted toward side-chain-oxidized sterols (oxysterols
and acids) and there may be underestimation of the levels of both
7a-hydroxycholesterol and 7a-hydroxycholest-4-en-3-one, which
may not be completely recovered in Fr-1 from SPE-1. If these
oxysterols are the target of study SPE-1 may be eluted with a
stronger solvent.
With the current method we have identiﬁed 25-hydroxycho-
lesterol and its hydroxylated (7a,25-dihydroxycholesterol,
o0.2 ng/ml) and oxidized products (7a,25-dihydroxycholest-
4-en-3-one, 1.2470.20 ng/ml) (see Fig. 3, Table S2). Although
GC–MS and LC-MS/MS analysis of plasma regularly identiﬁes
25-hydroxycholesterol, downstream metabolites are not usually
detected from healthy subjects because of their low abundance
[22,25,27]. Other oxysterols identiﬁed in adult plasma include
(25R),7a,26-dihydroxycholesterol (1.6570.39 ng/ml) and 7a,26-
dihydroxycholest-(25R)-4-en-3-one (5.5570.41 ng/ml). Again,
these metabolites are not usually investigated in GC–MS or
LC-MS/MS analysis of plasma from healthy subjects [27,30,53].
24S,25-Epoxycholesterol is an unusual oxysterol in that it is
formed in parallel to cholesterol via a shunt of the mevalonate
pathway by the same enzymes that synthesize cholesterol3β
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Fig. 2. (A) LC-MS reconstructed ion chromatograms (RICs) of m/z 534.4054710 ppm corresponding to monohydroxycholesterols modiﬁed by EADSA from representative
adult (top) and cerebrotendinous xanthomatosis (CTX) (bottom) plasma samples. The CTX patient was on treatment with chenodeoxycholic acid. The samples were
oxidized with cholesterol oxidase before GP derivatization to convert 3b-hydroxy-5-ene groups to their 3-oxo-4-ene equivalents. The MS3 (534.4-455.4-) spectra of
components eluting at (B) 7.70 min (24S-hydroxycholesterol), (C) 7.92 min (25-hydroxycholesterol), (D) 8.27 min ((25R),26-hydroxycholesterol), and (E) 10.53 min (7a-
hydroxycholesterol and 7a-hydroxycholest-4-en-3-one) are shown. Syn and anti conformers of (25R),26-hydroxycholesterol are observed eluting at 8.27 and 8.47 min, and
those of 7a-hydroxycholesterol at 10.53 and 11.08 min. Other peaks in (A) correspond to 7b-hydroxycholesterol, 7-oxocholesterol, and cholest-4-en-3b,6-diol eluting at
9.93, 10.07, and 10.94 min, respectively. It is likely that cholest-4-en-3b,6-diol is derived from 5,6-epoxycholesterol during the derivatization process. It is probable that
the concentration of 25-hydroxycholesterol is overestimated as there is tailing of the 24S-hydroxycholesterol peak into that of the 25-hydroxy isomer. Concentrations of
the most abundant metabolites are indicated in the chromatograms. Spectra were recorded on the LTQ-Orbitrap XL. %RA, percentage relative abundance.
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Fig. 3. (A) LC-MS RICs of m/z 550.4003710 ppm corresponding to GP-tagged dihydroxycholesterols from representative adult (top) and CTX (bottom) plasma samples.
The samples were treated with cholesterol oxidase before GP derivatization to convert 3b-hydroxy-5-ene groups to their 3-oxo-4-ene equivalents. The MS3 (550.4-
471.4-) spectra of components eluting at (B) 5.97 min (7a,25-dihydroxycholesterol and 7a,25-dihydroxycholest-4-en-3-one), (C) 6.48 min ((25R),7a,26-dihydroxycho-
lesterol and 7a,26-dihydroxycholest-(25R)-4-en-3-one)), and (D) 9.20 min (7a,12a-dihydroxycholesterol and 7a,12a-dihydroxycholest-4-en-3-one) are shown. 7a,25-
Dihydroxycholesterol/7a,25-dihydroxycholest-4-en-3-one and (25R),7a,26-dihydroxycholesterol/7a,26-dihydroxycholest-(25R)-4-en-3-one and 7a,12a-dihydroxycho-
lesterol/7a,12a-dihydroxycholest-4-en-3-one elute as syn and anti conformers at 5.97 and 6.78 min, 6.48 and 7.35 min, and 9.20 and 9.42 min, respectively. Spectra in
(B) and (C) are from a healthy adult, (D) is from a CTX patient on treatment with CDCA. Concentrations of the most abundant metabolites are indicated in the
chromatograms. Spectra were recorded on the LTQ-Orbitrap XL.
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plasma at low levels (2 ng/ml) by LC-MS/MS [27]. During our
sample preparation we ﬁnd that 24S,25-epoxycholesterol can
isomerize to 24-oxocholesterol [56]. Here we identify 24-oxocho-
lesterol at a level of o1 ng/ml (0.5970.85 ng/ml) in plasma,
presumably formed from the 24S,25-epoxide.
Cholenoic and cholestenoic acids
The acidic cholesterol metabolites identiﬁed in plasma with a
3b-hydroxy-5-ene or 3-oxo-4-ene structure include unsaturated
C24 precursors of primary bile acids, i.e., 3b-hydroxychol-5-en-
24-oic acid (1.7870.25 ng/ml), 3b,7a-dihydroxychol-5-en-24-
oic (4.1370.77 ng/ml), and 7a-hydroxy-3-oxochol-4-en-24-oic
(1.9170.26 ng/ml) acids (see Fig. 1). 3b,7a-Dihydroxychol-5-
en-24-oic and 7a-hydroxy-3-oxochol-4-en-24-oic acids are
potential precursors of chenodeoxycholic acid in bile acid
biosynthetic pathways [13,57]. The most abundant members of
the bile acid biosynthesis pathways [13] found in plasma are 3b-
hydroxycholest-(25R)-5-en-26-oic (82.6073.50 ng/ml), 3b,7a-
dihydroxycholest-(25R)-5-en-26-oic (47.4276.61 ng/ml), and7a-hydroxy-3-oxocholest-(25R)-4-en-26-oic (63.8975.44 ng/
ml; Fig. 4 and 5) acids; these data are consistent with ﬁndings
by others using GC–MS [31,53]. Surprisingly, 3b,7b-dihydrox-
ycholest-(25R)-5-en-26-oic acid (5.3670.81 ng/ml) was detected in
plasma, probably formed by the hepatic mitochondrial epimerization
reaction suggested by Shoda et al. [58].
In addition to 3b,7a- and 3b,7b-dihydroxycholest-(25R)-5-en-
26-oic acids in plasma (Fig. 5), two other dihydroxycholest-5-en-
26-oic acids were presumptively identiﬁed. Their MS3 spectra
suggest the locations of the additional hydroxyl groups to be on
the C-17 side chain. Tentative suggestions for the locations of the
additional hydroxyl groups are C-25 (5.2770.74 ng/ml, Fig. 5B)
and C-22 (2.2770.34 ng/ml, Fig. 5C). A third compound gave an
MS3 spectrum that could correspond to a dihydroxycholest-5-en-
26-oic acid (9.6371.46 ng/ml) or alternatively a trihydroxychol-
est-5-enone, possibly 3b,22,25-trihydroxycholest-5-en-24-one
(Fig. 5E). Whereas the major monohydroxycholestenoic acid in
adult plasma is 3b-hydroxycholest-(25R)-5-en-26-oic acid
(82.6073.50 ng/ml), a minor earlier eluting peak in the RIC of
m/z 548.3847 suggested the possible presence of the 25S isomer
(Fig. 4A). However, comparison of retention time and MSn spectra
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Fig. 4. LC-MS RICs of m/z 548.384775 ppm corresponding to 3b,x-dihydroxycholest-5-en-y-one and 3b-hydroxycholest-(25R)-5-en-26-oic acid after EADSA modiﬁcation
and found in plasma from a representative adult (top) and a CTX patient (bottom). The CTX patient was on treatment with CDCA. Chromatograms are normalized to the
most abundant peak. The samples were oxidized with cholesterol oxidase before GP derivatization to convert 3b-hydroxy-5-ene groups to their 3-oxo-4-ene equivalents.
The MS3 (548.4-469.3 -) spectra of components eluting at (B) 7.62 min (3b,x-dihydroxycholest-5-en-y-one) and (C) 7.98 min (3b-hydroxycholest-(25R)-5-en-26-oic
acid) from adult plasma are shown. The peak at 7.62 min in the chromatogram from the CTX patient gave a spectrum essentially identical to that in (B). Concentrations of
the most abundant metabolites are indicated in the chromatograms. Spectra were recorded on the LTQ-Orbitrap XL.
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A possible alternative structure is 3b,22-dihydroxycholest-5-en-
24-one (5.6470.50 ng/ml, Fig. 4B).
CTX
CTX is characterized by the absence of a functional CYP27A1
enzyme, which precludes the formation of (25R),26-hydroxycho-
lesterol and subsequent cholesten-(25R)-26-oic acids [59–61].
A consequence of this is that hydroxylated cholesterol metabolites
become shunted to alternate metabolic pathways. CTX in early
infancy can present with cholestatic liver disease, in early child-
hood with chronic diarrhea and cataracts, in later childhood with
tendon xanthomata and learning difﬁculties, and in adult life with
spastic paraparesis, with a fall in IQ or dementia, with ataxia and/
or dysarthria, with seizures, or with peripheral neuropathy [61].
Treatment is with CDCA. In Figs. 2–5 representative data are
shown for CTX patients on treatment with simvastatin and CDCA
at the time of sampling. From proﬁling the oxysterol content of
plasma of CTX patients the following diagnostic features were
deﬁned: (1) an absence of unsaturated C24 acids; (2) a major
reduction in the level of (25R),26-hydroxycholesterol (Fig. 2A); (3)elevation in the level of 7a-hydroxycholest-4-en-3-one; (4) an
absence of 3b-hydroxycholest-(25R)-5-en-26-oic, 3b,7a-dihydrox-
ycholest-(25R)-5-en-26-oic, and 7a-hydroxy-3-oxocholest-(25R)-
4-en-26-oic acids (Fig. 4A and 5A); and (5) a great enhancement in
the level of 7a,12a-dihydroxycholest-4-en-3-one (Fig. 3A). These
features were independent of treatment with CDCA and simvas-
tatin and are also observed for patients not on treatment. How-
ever, the levels of 7a-hydroxycholest-4-en-3-one are lower in
patients treated with CDCA than in untreated patients. These
diagnostic features, summarized in Table 2, are revealed from
the analysis of microliter quantities of plasma (easily obtainable
from infants) and in combination are unique to CTX. The absence
of a functional CYP27A1 enzyme is directly revealed here by an
absence of (or great reduction in) its direct metabolic products.
This may be seen as a diagnostic advantage over alternative
indirect tests based on an elevated abundance of metabolites
shunted into other bile acid/alcohol biosynthetic pathways.
Shotgun analysis
Shotgun ESI-MS in the negative-ion mode is appropriate for
the analysis of acidic cholesterol metabolites, particularly sulfates
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Fig. 5. (A) LC-MS RICs of m/z 564.3796710 ppm corresponding to dihydroxycholestenoic acids and trihydroxycholestenones after EADSA modiﬁcation from
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W.J. Grifﬁths et al. / Free Radical Biology and Medicine 59 (2013) 69–84 79
Table 2
Most important diagnostic features of CTX.
EADSA (plasma) Shotgun ESI-MS (plasma) Alternative (ESI-MS urine)
Absence of (or major reduction in) Abundant glucuronides of Abundant glucuronides of
 (25R),26-Hydroxycholesterol
 3b-Hydroxycholest-(25R)-5-en-26-oic acid
 3b,7a-Dihydroxycholest-(25R)-5-en-26-oic acid
 7a-Hydroxy-3-oxocholest-(25R)-4-en-26-oic acid
 Cholestanetetrols
 Cholestanepentols
 Cholestanehexols
 Cholestanetetrols
 Cholestanepentols
 Cholestanehexols
Elevation in
 7a-Hydroxycholest-4-en-3-one
 7a,12a-Dihydroxycholest-4-en-3-one
W.J. Grifﬁths et al. / Free Radical Biology and Medicine 59 (2013) 69–8480and sulfonates. The method is fast and simple and, when
performed at high resolution with exact mass measurements,
provides elemental formula information. When complemented by
MS2, structural information is also forthcoming; however, the
absence of online chromatography means that structural isomers
are not differentiated. Shotgun ESI-MS is highly complementary
to EADSA, as it is appropriate for sulfate esters, many of which are
located at C-3 and thus invisible to EADSA methodology. In terms
of clinical chemistry, shotgun ESI-MS offers two important
advantages over LC-MS-based EADSA: (1) it is high-throughput,
with MS and MS2 spectra being recorded in less than a minute,
and (2) by utilizing an individual nano-ESI nozzle for each sample,
problems of ‘‘carryover’’ are eliminated. Alternatively, a negative-
ion LC-ESI-MS approach could be adopted, in which case carry-
over between samples can be a problem, and the penalty of
chromatographically resolving isomers is paid in analysis time.
Further, authentic standards for sterol glucuronides and sulfates,
other than for cholesterol sulfate, are not commercially available,
making isomer identiﬁcation essentially impossible.
Adults and infants
Shotgun analysis was performed on the plasma extract deli-
pidated on SPE-1 and desalted on SPE-2. No further chromato-
graphy was performed, hence the resulting spectra were
complicated by numerous endogenous molecules other than
sterols, including free fatty acids, which tend to dominate the
negative-ion spectra, e.g., palmitic acid (m/z 255.2334) and stearic
acid (m/z 283.2645), and exogenous molecules such as plastici-
zers from polypropylene storage vessels (Fig. 6A). Despite this,
high-resolution accurate mass spectra of healthy infants and
adult plasma samples show the presence of sulfates of C19 and
C21 steroids, particularly DHEA (m/z 367.1590); isomers of hydro-
xyandrostanone, e.g., androsterone, epiandrosterone, and andros-
tenediol (m/z 369.1761); pregnenediol (m/z 397.2029); and
pregnenetriol (m/z 413.2005) (Fig. 6A). MS2 performed in the
LIT exploiting PQD allows the conﬁrmation of the presence of the
sulfate group by the characteristic fragment ion at 97 (HSO4
)
(Fig. 6C).
Shotgun analysis of CTX plasma
In comparison to normal plasma, the untreated CTX patient
gave a spectrum dramatically different at the high m/z end (m/z
600–650), where peaks characteristic of glucuronides of choles-
tanetetrols (m/z 611.3798), pentols (m/z 627.3737), and hexols
(m/z 643.3680) are evident (cf. Fig. 6A and B) [60,62]. Whereas
accurate mass measurements (o5 ppm) made at high resolution
suggest an elemental composition, further structural information
is forthcoming by performing MS2. This is evident in the MS2
spectra of the three glucuronides, which show neutral losses of60, 118, 176, and 194 characteristic of the glucuronic acid group
[63] (Fig. 6D). From the MS2 spectra we are unable to deﬁne the
stereochemistry of the cholestane skeleton; however, detailed
studies on glucuronides found in the bile of a CTX patient indicate
a predominant 5b-cholestane-3a,7a,12a,25-tetrol skeleton with
glucuronidation at the 3a position [64]. Alternative and additional
sites of side-chain hydroxylation are at C-22, C-23, and C-24 [60].
In patients on CDCA treatment, [MH] ions corresponding to
these glucuronides are absent from the shotgun spectra.
Shotgun analysis of plasma from a patient with suspected
hydroxysteroid dehydrogenase 3B7 deﬁciency
Hydroxysteroid dehydrogenase (HSD) 3B7 (also known as
3b-hydroxy-C27-steroid oxidoreductase or 3b-hydroxysteroid-D5-
C27-steroid dehydrogenase) is the enzyme responsible for convert-
ing C27 sterols with a 3b,7a-dihydroxy-5-ene structure to those with
a 7a-hydroxy-3-oxo-4-ene structure in the bile acid biosynthesis
pathway. An absence of functional enzyme results in a buildup of
sterols and bile acids retaining the 3b-hydroxy-5-ene function [61].
In the circulation these are found sulfated and/or glucuronidated.
Shown in Fig. 7 is the shotgun ESI-MS spectrum of a child with
suspected HSD3B7 deﬁciency. It is likely that sulfation is predomi-
nantly at position C-3, in which case many of the metabolites
observed in this spectrumwill be transparent to EADSA. Thus, in this
case shotgun ESI-MS provides invaluable information that would be
lost by simply performing EADSA. HSD3B7 deﬁciency may present
with neonatal conjugated hyperbilirubinemia, rickets, hepatome-
galy, pruritus, and steatorrhea. Provided that liver damage is not too
advanced at the time of diagnosis, the condition responds extremely
well to bile acid replacement therapy [61].Caveats
In this article we have extolled the virtues of EADSA in
combination with shotgun ESI-MS for the analysis of cholesterol
metabolites. The two methods are complementary, as EADSA
works with steroids possessing a free 3b-hydroxy or oxo group
and shotgun negative-ion ESI-MS works most effectively for
steroids conjugated with a strongly acidic group, e.g., sulfuric
acid ester, in which the site of modiﬁcation is often at C-3, making
the molecule transparent to EADSA, but readily ionized by
negative-ion ESI.
To the best of our knowledge, EADSA offers sensitivity advan-
tages for the analysis of sterols that exceed those of any other
methodology. There are, however, a number of disadvantages of
EADSA methodology, which should be considered.1. Steroids with a free 3a-hydroxy group are not oxidized by
cholesterol oxidase [47]; thus, e.g., primary bile acids cannot
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Fig. 6. Negative-ion ESI-MS spectra of plasma samples from (A) a control infant and (B) a boy with CTX not on treatment. (C) ESI-MS2 spectrum of the ionm/z 367 from the
control sample. (D) ESI-MS2 spectrum of the ion m/z 611 from the boy with CTX. Peaks labeled with an asterisk correspond to C19 and C21 steroid sulfates, those with a
ﬁlled square to oxysterol glucuronides, and those with a ﬁlled circle to fatty acids. Spectra were recorded on the LTQ-Orbitrap XL. Spectra in (A) and (B) were recorded at
high resolution, (C) and (D) utilized the ion-trap detector.
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However, this problem can be circumvented by the use of
3a-hydroxysteroid dehydrogenase instead of cholesterol oxi-
dase, which generates the 3-ketone suitable for subsequent
derivatization.2. A problem with all steroid derivatization reactions is the
prevalence of labile hydroxy groups to be eliminated as water
during the derivatization process. This is seen with the method
presented here for 7a-hydroxy-3-oxocholest-(25R)-4-en-26-
oic acid, which undergoes dehydration to the 4,6-diene despite
the reaction being performed at room temperature.3. Steroids possessing an epoxide group are labile in acidic solvents
and we ﬁnd that 24S,25-epoxycholesterol becomes isomerized to
the 24-ketone, hydrolyzed to the 24,25-diol, and methanolyzed
to the 24-hydroxy-25-methyl ether (and/or 25-hydroxy-24-
methyl ether) during the EADSA process. 5,6-Epoxycholesterol
becomes hydrolyzed to the 3b,5,6-triol, which eliminates water
to leave the cholest-4-ene-3b,6-diol [56].4. A disadvantage of the hydrazone derivative is that its forma-
tion is reversible in acidic solvents. This precludes the storage
of derivatized steroids in acidic solvents and dictates that
GP-derivatized steroids are not kept for long periods (424 h)
in their injection solvent before injection onto the LC system.
However, we ﬁnd that when stored in 100% methanol GP-
derivatized steroids are stable.5. A consequence of derivatization with a hydrazine reagent is
the formation of syn and anti hydrazones. These are oftenresolved in our chromatography system, highlighting the
quality of the chromatography, but complicating the ultimate
chromatogram.6. The chromatographic method described here utilizes a Hyper-
sil Gold RP column. By employing the sample preparation
procedure described here columns have an exceedingly long
lifetime (all columns purchased in the past 4 years are still in
use today with no reduction in performance). However, there
is some batch-to-batch variation, which means that with some
columns 25-hydroxycholesterol is only partially resolved from
the 24S-isomer. This problem can be overcome by lengthening
the gradient but at the expense of throughput.7. In the EADSA methodology reported here quantiﬁcation is
made using 24(R/S)-[2H6]hydroxycholesterol as the internal
standard. Cholesterol oxidase from Streptomyces sp. has similar
activities toward most sterols with a 3b-hydroxy-5-ene struc-
ture [47], and we have found that 3-oxo-4-ene sterols once
derivatized with GP-hydrazine give essentially the same ESI
response irrespective of other functional groups present [43],
allowing good quantitative estimates to be made without the
inclusion of additional reference standards other than
[2H7]cholesterol for sterols eluting in Fr-3 from SPE-1. How-
ever, the sample preparation protocol described here has been
designed with side-chain-oxidized sterols and cholestenoic
acids in mind, and it is likely that 7a-hydroxycholesterol and
other ring-oxidized sterols are not fully eluted from SPE-1 in
Fr-1; hence their amount is probably underestimated. This is
Fig. 7. (A) Negative-ion ESI-MS spectrum of a plasma sample from an infant with suspected HSD3B7 deﬁciency. The inset shows the high m/z range 640–700. MS2 spectra
ions of (B) m/z 280, (C) m/z 328 and 657, and (D) m/z 336 and 673, corresponding to cholest-5-ene-3b,x-diol disulfate [M2H]2 , cholest-5-ene-3b,x-diol 3-sulfate and
x-glucuronide [M2H]2 and [MH] , and cholest-5-ene-3b,x,y-triol 3-sulfate and x-glucuronide [M2H]2 and [MH] ions, respectively, are shown. Sulfation is
assumed at C-3, and x and y are drawn on the side chain. Peaks labeled with an asterisk correspond to oxysterol mono- or disulfates, those with a ﬁlled triangle to
oxysterols sulfated and glucuronidated, that with a diamond to taurine-conjugated bile acid sulfates, and that with a ﬁlled circle to fatty acids. Spectra were recorded on
the LTQ-Orbitrap XL and at high resolution.
W.J. Grifﬁths et al. / Free Radical Biology and Medicine 59 (2013) 69–8482easily rectiﬁed by using a stronger eluent to elute 7a-hydro-
xycholesterol from SPE-1.8. A number of sterols can exist naturally in their 3-oxo-4-ene
and 3b-hydroxy-5-ene forms; this dictates the analysis of A
(with cholesterol oxidase) and B (without cholesterol oxidase)
fractions, and the difference A  B equals the amount of free
3b-hydroxy-5-ene metabolite. In most studies we use DHEA
3-sulfate, an abundant steroid present in plasma, not oxidized
by cholesterol oxidase, as a natural internal standard to allow
the normalization of fraction B to the fraction A equivalents.
Alternatively, 22R-[2H7]hydroxycholest-4-en-3-one can be
used as an internal standard for B fractions.
Despite these caveats, the advantages of EADSA lie in its
simplicity and robustness, offering greatly improved sensitivity
for the analysis of steroids and sterols.Acknowledgments
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